Meeting
2022 ASCO Annual Meeting
Humoral and cellular immune response to Sars-CoV-2 wild-type and variants of concern following 3-dose vaccination in a large cohort of adults with cancer: The SerOzNET study.
Authors
Eva Segelov
Monash Health, Melbourne, Australia
Eva Segelov , Amy Body , Vi Thi Thao Luong , Veronica Aedo Lopez , Luxi Lal , Hesham Abdulla , Stuart Turville , Zin Naing , Stephen Opat , Robert McCuaig , Sudha Rao , Katie Lineburg , Corey Smith , Chandini MacIntyre , Elizabeth Stephanie Ahern
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Health Promotion/Behaviors
Clinical Trial Registration Number
ACTRN12621001004853
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA12065)
DOI
10.1200/JCO.2022.40.17_suppl.LBA12065
Abstract #
LBA12065
Poster Bd #
311
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
The effect of corticosteroid on immunogenicity of SARS-CoV-2 vaccines in solid cancer patients.
First Author: Chayanee Samdaengpan
Poster
2023 ASCO Annual Meeting
Immunogenicity after COVID-19 vaccination in patients with solid tumor and hospital staff: A prospective single-center observational study.
First Author: Yuki Katsuya
Poster
2022 ASCO Annual Meeting
Longitudinal immunological responses of COVID-19 vaccination in patients with solid tumors on active treatment: A pilot study.
First Author: Lifen Cao
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.
First Author: Pankaj Gaur